Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Director Sells $4,638,487.08 in Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Director Johan Wedell-Wedellsborg sold 168,244 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $27.57, for a total transaction of $4,638,487.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of YMAB traded down $0.41 on Thursday, hitting $27.46. 757 shares of the stock traded hands, compared to its average volume of 126,446. The company has a quick ratio of 9.04, a current ratio of 9.04 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $953.66 million and a P/E ratio of -18.44. The stock’s 50 day moving average is $23.66 and its two-hundred day moving average is $22.91. Y-mAbs Therapeutics, Inc has a 1 year low of $15.17 and a 1 year high of $31.00.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). Research analysts forecast that Y-mAbs Therapeutics, Inc will post -2.09 EPS for the current year.

Several analysts have issued reports on YMAB shares. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Saturday, August 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target (up previously from $36.00) on shares of Y-mAbs Therapeutics in a report on Monday, June 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. Six research analysts have rated the stock with a buy rating, Y-mAbs Therapeutics currently has an average rating of “Buy” and a consensus target price of $31.40.

Several institutional investors and hedge funds have recently made changes to their positions in YMAB. BlackRock Inc. lifted its stake in shares of Y-mAbs Therapeutics by 212.6% during the second quarter. BlackRock Inc. now owns 1,153,831 shares of the company’s stock valued at $26,387,000 after buying an additional 784,672 shares during the period. Artal Group S.A. purchased a new position in shares of Y-mAbs Therapeutics during the second quarter valued at approximately $9,148,000. Cormorant Asset Management LP lifted its stake in shares of Y-mAbs Therapeutics by 39.8% during the second quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $22,870,000 after buying an additional 284,518 shares during the period. Vanguard Group Inc. lifted its stake in shares of Y-mAbs Therapeutics by 72.0% during the second quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock valued at $11,196,000 after buying an additional 205,021 shares during the period. Finally, AXA purchased a new position in shares of Y-mAbs Therapeutics during the second quarter valued at approximately $3,560,000. 29.51% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: What is Elliott Wave theory?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.